Attention-deficit hyperactivity disorder

PO ,

Adult

Attention-deficit hyperactivity disorder:

40 mgQD; increase after a minimum of 3 days to a target dose of approximately 80 mg/day in 1-2 divided doses; 100 mg/day may be considered after 2 to 4 additional wks in patients who have not achieved adequate response on lower doses. Max. 100 mg/d.

Pediatric ≥ 6 yrs

Attention-deficit hyperactivity disorder:

up to 70 kg , 0.5 mg/kg/day; increase after a minimum of 3 days to a target dose of 1.2 mg/kg/day; 1.4 mg/kg/day or 100 mg (whichever is less).

over 70 kg , the same as adult.

hypersensitivity to atomoxetine product;

MAO inhibitors (atomoxetine should not be administered during therapy with or within 2 weeks of discontinuing an MAOI);

narrow angle glaucoma (increased risk of mydriasis).

M or L: Hypertension, palpitation, tachycardia; weight loss; rash; constipation, nausea, vomiting, indigestion, loss of appetite, xerostomia; dizziness, headache, insomnia, paresthesia, somnolence; mood swings; difficulty passing urine, urinary retention; disorder of ejaculation, dysmenorrhea, erectile dysfunction, prostatitis, reduced  libido.   

R: Injury of liver; dyskinesia, seizure; suicidal thoughts;

priapism.

Take with or without food.

Swallow the capsule whole. Do not crush, break, or chew it.